Yingying Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yingying Lu has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Qi Yang
Department of Critical Care Medicine, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China
3 shared publications- Weiqin Li
Department of Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
3 shared publications Xiaojie Ma
Department of Critical Care Medicine, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China
3 shared publications- Guotao Lu
Pancreatic Center, Department of Gastroenterology, Yangzhou Key Laboratory of Pancreatic Disease, The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China
2 shared publications Lin Gao
Department of Critical Care Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, No. 305 Zhongshan East Road, Nanjing, 210002 Jiangsu, China
2 shared publicationsNan Ma
Department of Critical Care Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, No. 305 Zhongshan East Road, Nanjing, 210002 Jiangsu, China
2 shared publications
Latest Publications
- 3 May 2024
- Published by Elsevier in The American Journal of Pathology
- Vol. 194 (8) , 1494-1510
Adipose Triglyceride Lipase–Mediated Adipocyte Lipolysis Exacerbates Acute Pancreatitis Severity in Mouse Models and Patients
- 3 May 2024
- Published by Elsevier in The American Journal of Pathology
- Vol. 194 (8) , 1494-1510
Adipose Triglyceride Lipase–Mediated Adipocyte Lipolysis Exacerbates Acute Pancreatitis Severity in Mouse Models and Patients
- Open Access
- 25 October 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 125 (Pt A) , 110950
HDL inhibits pancreatic acinar cell NLRP3 inflammasome activation and protect against acinar cell pyroptosis in acute pancreatitis
- 25 October 2023
- Published by Elsevier in International Immunopharmacology
- Vol. 125 (Pt A) , 110950
Open AccessHDL inhibits pancreatic acinar cell NLRP3 inflammasome activation and protect against acinar cell pyroptosis in acute pancreatitis
- Open Access
- 1 January 2021
- Published by Wiley in Mediators of Inflammation
- Vol. 2021 (1)
The Proresolving Lipid Mediator Maresin1 Alleviates Experimental Pancreatitis via Switching Macrophage Polarization
Background and Purpose. Previous studies showed that Maresin1 (MaR1), one of the metabolites from docosahexaenoic acid (DHA), could alleviate acute inflammation and prompt inflammation resolution. Also, it attenuated pancreatic injury in caerulein‐induced acute pancreatitis (AP) in mice. However, the mechanisms underlying this suppression of inflammation and AP remain unknown. Method. Repeated caerulein injection was used to induce AP and chronic pancreatitis (CP) models in mice. The histopathological and serological changes were examined for evaluating the severity of the AP model, and flow cytometry was used for detecting macrophage phagocytosis and phenotype. Meanwhile, clodronate liposomes were used for macrophage depletion in mice. Finally, the CP model was adopted to further observe the protective effect of MaR1. Result. MaR1 administration manifested the improved histopathological changes and the lower serum levels of amylase and lipase. However, MaR1 played no protective role in the pancreatic acinar cell line in vitro. It obviously reduced the macrophage infiltration in the injured pancreas, especially M1‐type macrophages. After macrophage clearance, MaR1 showed no further protection in vivo. This study also demonstrated that MaR1 could alleviate fibrosis to limit AP progression in the CP model. Conclusion. Our data suggests that MaR1 was a therapeutic and preventive target for AP in mice, likely operating through its effects on decreased macrophage infiltration and phenotype switch.
- 1 January 2021
- Published by Wiley in Mediators of Inflammation
- Vol. 2021 (1)
Open AccessThe Proresolving Lipid Mediator Maresin1 Alleviates Experimental Pancreatitis via Switching Macrophage Polarization
Background and Purpose. Previous studies showed that Maresin1 (MaR1), one of the metabolites from docosahexaenoic acid (DHA), could alleviate acute inflammation and prompt inflammation resolution. Also, it attenuated pancreatic injury in caerulein‐induced acute pancreatitis (AP) in mice. However, the mechanisms underlying this suppression of inflammation and AP remain unknown. Method. Repeated caerulein injection was used to induce AP and chronic pancreatitis (CP) models in mice. The histopathological and serological changes were examined for evaluating the severity of the AP model, and flow cytometry was used for detecting macrophage phagocytosis and phenotype. Meanwhile, clodronate liposomes were used for macrophage depletion in mice. Finally, the CP model was adopted to further observe the protective effect of MaR1. Result. MaR1 administration manifested the improved histopathological changes and the lower serum levels of amylase and lipase. However, MaR1 played no protective role in the pancreatic acinar cell line in vitro. It obviously reduced the macrophage infiltration in the injured pancreas, especially M1‐type macrophages. After macrophage clearance, MaR1 showed no further protection in vivo. This study also demonstrated that MaR1 could alleviate fibrosis to limit AP progression in the CP model. Conclusion. Our data suggests that MaR1 was a therapeutic and preventive target for AP in mice, likely operating through its effects on decreased macrophage infiltration and phenotype switch.
- Open Access
- 1 August 2020
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 9 (8) , 4656-4665
Effects of Helicobacter pylori infection and interleukin 6 on the expression of ITIH4 in human gastric cancer cells
Background: Human inter-α-trypsin inhibitor heavy chain 4 (ITIH4) is an acute phase response protein that is positively regulated by interleukin-6 (IL-6), suggesting that ITIH4 can be used as an early serological biomarker of gastric cancer. Methods: The mechanism of ITIH4 elevation in gastric cancer cells was investigated via Helicobacter pylori (H. pylori) with or without recombinant human interleukin-6 (rhIL-6) in human gastric cell line AGS cells. The messenger RNA (mRNA) expressions of ITIH4 and IL-6 in AGS cells were detected with real-time quantitative polymerase chain reaction (qPCR), while the expression of ITIH4 protein and IL-6 in AGS cells was detected with Western blot and enzyme-linked immunosorbent assay (ELISA) methods. Results: We found that the mRNA and protein expressions of ITIH4 started to increase synchronously at 3 hours (h), peaked at 12 h, and then declined to normal a level at 24 h in AGS cells after H. pylori infection. Interestingly, the expression patterns of ITIH4 were positively correlated to IL-6 expression levels. In the ITIH4 expression experiment with IL-6 administration, the expression level of ITIH4 began to increase at a concentration of 6.25 ng/mL with rhIL-6 administration, reach a peak, and plateau at a concentration of 25 ng/mL of rhIL-6. The expression patterns of ITIH4 in AGS cells induced by H. pylori infection were closely related to the infection of H. pylori and the level of IL-6. Conclusions: The detection of ITIH4 and IL-6 during H. pylori infection may be useful for the screening of early gastric cancer.
- 1 August 2020
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 9 (8) , 4656-4665
Open AccessEffects of Helicobacter pylori infection and interleukin 6 on the expression of ITIH4 in human gastric cancer cells
Background: Human inter-α-trypsin inhibitor heavy chain 4 (ITIH4) is an acute phase response protein that is positively regulated by interleukin-6 (IL-6), suggesting that ITIH4 can be used as an early serological biomarker of gastric cancer. Methods: The mechanism of ITIH4 elevation in gastric cancer cells was investigated via Helicobacter pylori (H. pylori) with or without recombinant human interleukin-6 (rhIL-6) in human gastric cell line AGS cells. The messenger RNA (mRNA) expressions of ITIH4 and IL-6 in AGS cells were detected with real-time quantitative polymerase chain reaction (qPCR), while the expression of ITIH4 protein and IL-6 in AGS cells was detected with Western blot and enzyme-linked immunosorbent assay (ELISA) methods. Results: We found that the mRNA and protein expressions of ITIH4 started to increase synchronously at 3 hours (h), peaked at 12 h, and then declined to normal a level at 24 h in AGS cells after H. pylori infection. Interestingly, the expression patterns of ITIH4 were positively correlated to IL-6 expression levels. In the ITIH4 expression experiment with IL-6 administration, the expression level of ITIH4 began to increase at a concentration of 6.25 ng/mL with rhIL-6 administration, reach a peak, and plateau at a concentration of 25 ng/mL of rhIL-6. The expression patterns of ITIH4 in AGS cells induced by H. pylori infection were closely related to the infection of H. pylori and the level of IL-6. Conclusions: The detection of ITIH4 and IL-6 during H. pylori infection may be useful for the screening of early gastric cancer.
- 20 May 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (15_suppl) , e17072
Prognosis of ovarian cancer in the United States during 1973 to 2015.
E17072 Background: Ovarian cancer is the first leading cause of cancer death among gynecologic malignancies. Despite significant efforts to improve treatment strategies, the prognosis of patients with ovarian cancer remains poor. Different diagnostic period and the occurrence of distant metastases may have different impacts on prognosis. In this study, we sought to describe the impact of distant metastases and different diagnostic period on prognosis of ovarian cancer. Methods: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify patients diagnosed with ovarian cancer from year 1973 to year 2015. Kaplan-Meier method was used to estimate the overall survival (OS) and Log-Rank test was used to compare the difference between groups. Results: Total 152729 patients with ovarian cancer were included. Median age was 62 years. The overall rates of distant lymph node metastases, bone, brain, liver and lung were 2.9%, 1.0%, 0.2%, 6.6% and 5.6%. Median overall survival (OS) was 30 months, 6 months, 9 months, 20 months and 20 months for pure distant lymph node metastases, brain metastases, bone metastases, lung metastases and liver metastases, respectively. Patients who were diagnosed from year 2010 to year 2015 had significantly improved OS compared with patients who were diagnosed from year 1973 to year 2009 (54 months vs. 47 months, P < 0.0001). Patients with pure distant lymph node metastases who were diagnosed from year 2010 to year 2015 also had significantly improved OS compared with patients who were diagnosed from year 1973 to year 2009 (30 months vs. 24 months, P = 0.0002). In addition, we also observed a trend of longer OS in patients with bone metastases diagnosed from year 2014 to year 2015 compared with patients who were diagnosed year 2010 to year 2013 (10 months vs. 7 months, P = 0.05). Conclusions: The results of this analysis indicated an improved prognosis in patients with ovarian cancer from 2010 to 2014, especially for patients with distant lymph node metastases. In addition, novel treatment strategies are needed for patients with distant visceral metastases.
- 20 May 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (15_suppl) , e17072
Prognosis of ovarian cancer in the United States during 1973 to 2015.
E17072 Background: Ovarian cancer is the first leading cause of cancer death among gynecologic malignancies. Despite significant efforts to improve treatment strategies, the prognosis of patients with ovarian cancer remains poor. Different diagnostic period and the occurrence of distant metastases may have different impacts on prognosis. In this study, we sought to describe the impact of distant metastases and different diagnostic period on prognosis of ovarian cancer. Methods: The Surveillance, Epidemiology, and End Results (SEER) database was used to identify patients diagnosed with ovarian cancer from year 1973 to year 2015. Kaplan-Meier method was used to estimate the overall survival (OS) and Log-Rank test was used to compare the difference between groups. Results: Total 152729 patients with ovarian cancer were included. Median age was 62 years. The overall rates of distant lymph node metastases, bone, brain, liver and lung were 2.9%, 1.0%, 0.2%, 6.6% and 5.6%. Median overall survival (OS) was 30 months, 6 months, 9 months, 20 months and 20 months for pure distant lymph node metastases, brain metastases, bone metastases, lung metastases and liver metastases, respectively. Patients who were diagnosed from year 2010 to year 2015 had significantly improved OS compared with patients who were diagnosed from year 1973 to year 2009 (54 months vs. 47 months, P < 0.0001). Patients with pure distant lymph node metastases who were diagnosed from year 2010 to year 2015 also had significantly improved OS compared with patients who were diagnosed from year 1973 to year 2009 (30 months vs. 24 months, P = 0.0002). In addition, we also observed a trend of longer OS in patients with bone metastases diagnosed from year 2014 to year 2015 compared with patients who were diagnosed year 2010 to year 2013 (10 months vs. 7 months, P = 0.05). Conclusions: The results of this analysis indicated an improved prognosis in patients with ovarian cancer from 2010 to 2014, especially for patients with distant lymph node metastases. In addition, novel treatment strategies are needed for patients with distant visceral metastases.
- Open Access
- 12 July 2017
- Published by Spandidos Publications in Oncology Letters
- Vol. 14 (3) , 3611-3615
Expression and clinical significance of SATB1 and TLR4 in breast cancer
This study investigated the expression of special AT‑rich sequence‑binding protein 1 (SATB1) and toll‑like receptor 4 (TLR4) protein in breast cancer and its clinical significance. We collected breast cancer tissues from 120 patients and adjacent non‑cancerous tissue from 53 patients. SATB1 was expressed in 89 cases of breast cancer (74.17%) and in 7 cases of adjacent non‑cancerous tissue (13.21%). TLR4 was expressed in 70 cases of breast cancer tissues (58.33%) and in 48 cases of adjacent non‑cancerous tissue (90.57%). The differences of SATB and TLR4 in breast cancer and adjacent non‑cancerous tissue were statistically significant. We found a negative correlation between the expression of SATB1 and TLR4 (r=‑0.624, P<0.05). The expression of SATB1 and TLR4 were not significantly correlated with age, menopause, and PR and HER‑2 protein expression, but were significantly correlated with tumor size, local lymphatic metastasis, histopathological grade, tumor stage, and ER protein expression (P<0.05). Overall, SATB1 and TLR4 proteins are involved in the development of breast cancer, a finding of great significance to identify therapeutic targets and prognosis markers for breast cancer.
- 12 July 2017
- Published by Spandidos Publications in Oncology Letters
- Vol. 14 (3) , 3611-3615
Open AccessExpression and clinical significance of SATB1 and TLR4 in breast cancer
This study investigated the expression of special AT‑rich sequence‑binding protein 1 (SATB1) and toll‑like receptor 4 (TLR4) protein in breast cancer and its clinical significance. We collected breast cancer tissues from 120 patients and adjacent non‑cancerous tissue from 53 patients. SATB1 was expressed in 89 cases of breast cancer (74.17%) and in 7 cases of adjacent non‑cancerous tissue (13.21%). TLR4 was expressed in 70 cases of breast cancer tissues (58.33%) and in 48 cases of adjacent non‑cancerous tissue (90.57%). The differences of SATB and TLR4 in breast cancer and adjacent non‑cancerous tissue were statistically significant. We found a negative correlation between the expression of SATB1 and TLR4 (r=‑0.624, P<0.05). The expression of SATB1 and TLR4 were not significantly correlated with age, menopause, and PR and HER‑2 protein expression, but were significantly correlated with tumor size, local lymphatic metastasis, histopathological grade, tumor stage, and ER protein expression (P<0.05). Overall, SATB1 and TLR4 proteins are involved in the development of breast cancer, a finding of great significance to identify therapeutic targets and prognosis markers for breast cancer.
- Open Access
- 1 January 2013
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 19 (8) , 1322-6
Multiple endocrine neoplasia type 1 with upper gastrointestinal hemorrhage and perforation: A case report and review
Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary syndrome known to predispose subjects to endocrine neoplasms in a variety of tissues such as the parathyroid glands, pituitary gland, pancreas and gastrointestinal tract. We herein report a patient with a past history of pituitary adenoma, presenting with symptoms of chronic diarrhea for nearly one year and a sudden upper gastrointestinal hemorrhage as well as perforation without signs. Nodules in the duodenum and in the uncinate process and tail of pancreas and enlargement of the parathyroid glands were detected on preoperative imaging. Gastroscopy revealed significant ulceration and esophageal reflux diseases. The patient underwent subtotal parathyroidectomy and autotransplantation, pylorus-preserving pancreaticoduodenectomy and pancreatic tail resection and recovered well. The results observed in our patient suggest that perforation and bleeding of intestine might be symptoms of Zollinger-Ellison Syndrome in patients with MEN1.
- 1 January 2013
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 19 (8) , 1322-6
Open AccessMultiple endocrine neoplasia type 1 with upper gastrointestinal hemorrhage and perforation: A case report and review
Multiple endocrine neoplasia type 1 (MEN1) is a rare hereditary syndrome known to predispose subjects to endocrine neoplasms in a variety of tissues such as the parathyroid glands, pituitary gland, pancreas and gastrointestinal tract. We herein report a patient with a past history of pituitary adenoma, presenting with symptoms of chronic diarrhea for nearly one year and a sudden upper gastrointestinal hemorrhage as well as perforation without signs. Nodules in the duodenum and in the uncinate process and tail of pancreas and enlargement of the parathyroid glands were detected on preoperative imaging. Gastroscopy revealed significant ulceration and esophageal reflux diseases. The patient underwent subtotal parathyroidectomy and autotransplantation, pylorus-preserving pancreaticoduodenectomy and pancreatic tail resection and recovered well. The results observed in our patient suggest that perforation and bleeding of intestine might be symptoms of Zollinger-Ellison Syndrome in patients with MEN1.
- Open Access
- 1 January 2008
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 14 (35) , 5403-5411
Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line
AIM: To investigate the effect and mechanism of action of erlotinib, an epidermal growth factor receptor (EGFR) small molecule tyrosine kinase inhibitor (TKI), in the human pancreatic cancer cell line BxPC-3 both in vitro and in vivo. METHODS: In vitro, human pancreatic cancer cell line BxPC-3 was exposed to varying concentrations of erlotinib, and its effects on proliferation, cell cycle distribution, apoptosis and the expression of pro- and antiapoptotic factors such as bcl-2, bcl-xl, bax and bak, and the expression of vascular endothelial cell growth factor (VEGF) were measured with 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, flow cytometric analysis, terminal deoxynucleotidyl transferase-mediated nick end labeling assay (TUNEL), and reverse transcription-polymerase chain reaction (RT-PCR). Potential effect of erlotinib on angiogenesis was examined by tube formation assay. Tumor growth suppression was observed in xenografted nude mice with pancreatic cancer in vivo. Immunohistochemical (IHC) staining for EGFR and factor VIII-related antigen was undertaken to detect the microvessel density and VEGF expression in tumor tissue in xenograft nude mice. RESULTS: Erlotinib, as a single agent, repressed BxPC-3 cell growth in a dose-dependent manner, triggered G1 arrest and induced cell apoptosis, and suppressed capillary formation of endothelium in vitro. Expressions of VEGF were significantly down-regulated at a high concentration of 200 μmol/L, however, the expressions of bcl-2 and bcl-xl were decreased at 50 μmol/L. In vivo, Erlotinib-treated mice demon-strated a reduced tumor volume, weight and microvessel density as compared to the control. IHC staining showed decreased expression of EGFR and RT-PCR had lower VEGF expression in treated mice. CONCLUSION: The in vitro and in vivo findings provide evidence that BxPC-3 cells are inhibited with erlotinib treatment. Inhibition of EGFR may be a promising adjuvant chemotherapy strategy in pancreatic cancer treatment.
- 1 January 2008
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 14 (35) , 5403-5411
Open AccessAnti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line
AIM: To investigate the effect and mechanism of action of erlotinib, an epidermal growth factor receptor (EGFR) small molecule tyrosine kinase inhibitor (TKI), in the human pancreatic cancer cell line BxPC-3 both in vitro and in vivo. METHODS: In vitro, human pancreatic cancer cell line BxPC-3 was exposed to varying concentrations of erlotinib, and its effects on proliferation, cell cycle distribution, apoptosis and the expression of pro- and antiapoptotic factors such as bcl-2, bcl-xl, bax and bak, and the expression of vascular endothelial cell growth factor (VEGF) were measured with 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, flow cytometric analysis, terminal deoxynucleotidyl transferase-mediated nick end labeling assay (TUNEL), and reverse transcription-polymerase chain reaction (RT-PCR). Potential effect of erlotinib on angiogenesis was examined by tube formation assay. Tumor growth suppression was observed in xenografted nude mice with pancreatic cancer in vivo. Immunohistochemical (IHC) staining for EGFR and factor VIII-related antigen was undertaken to detect the microvessel density and VEGF expression in tumor tissue in xenograft nude mice. RESULTS: Erlotinib, as a single agent, repressed BxPC-3 cell growth in a dose-dependent manner, triggered G1 arrest and induced cell apoptosis, and suppressed capillary formation of endothelium in vitro. Expressions of VEGF were significantly down-regulated at a high concentration of 200 μmol/L, however, the expressions of bcl-2 and bcl-xl were decreased at 50 μmol/L. In vivo, Erlotinib-treated mice demon-strated a reduced tumor volume, weight and microvessel density as compared to the control. IHC staining showed decreased expression of EGFR and RT-PCR had lower VEGF expression in treated mice. CONCLUSION: The in vitro and in vivo findings provide evidence that BxPC-3 cells are inhibited with erlotinib treatment. Inhibition of EGFR may be a promising adjuvant chemotherapy strategy in pancreatic cancer treatment.